- DESCRIPTION
- TABLE OF CONTENTS
- METHODOLOGY
- DOWNLOAD PDF
Multiplex Assays Market by Product & Service (Consumable, Instrument), Type (Protein, Nucleic Acid), Technology (Flow Cytometry), Application [R&D, Diagnostics (Infectious Disease, Cancer)], End User (Hospital, Research Institute)-Global Forecast to 2031
USD 10.65 BN
MARKET SIZE, 2031
CAGR 8.3%
(2026-2031)
350
REPORT PAGES
312
MARKET TABLES
MULTIPLEX ASSAYS MARKET SIZE, SHARE & GROWTH SNAPSHOT
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global multiplex assay market is projected to grow from USD 7.15 billion in 2026 to USD 10.65 billion by 2031, at a CAGR of 8.3% during the forecast period. The market was valued at USD 6.65 billion in 2025. The use of multiplex assays is driven by the need for laboratories to manage a growing number of samples, reduce turnaround times, and address increasingly complex disease mechanisms. There is particularly high demand for methods that extract multiple biomarkers from a single sample.
KEY TAKEAWAYS
-
BY REGION
The Asia Pacific region is expected to experience the fastest growth, driven by the expansion of laboratory capacity, increased use of molecular testing, and ongoing funding in countries like China, India, and Japan. Meanwhile, North America is projected to maintain the largest revenue base in 2025, owing to established suppliers and well-developed diagnostic networks.
-
BY PRODUCT & SERVICE
By product & service, consumables accounted for the largest share of 67.9% in 2025, primarily because they are included in every testing cycle rather than being linked to one-time capital purchases.
-
BY TYPE
By type, protein multiplex assays are expected to register the highest CAGR of 8.6% during the forecast period.
-
BY TECHNOLOGY
By technology, multiplex real-time PCR is expected to dominate the market in 2025 because of its broad application in immune profiling and cell analysis.
-
BY APPLICATION
By application, the research & development segment accounted for the largest market share of 61.6% in 2025.
-
BY END USER
By end user, pharmaceutical & biotechnology companies are projected to witness the highest CAGR due to increasing use in companion diagnostics and clinical research.
-
COMPETITIVE LANDSCAPE - KEY PLAYERS
Thermo Fisher Scientific, Inc. (US), Illumina, Inc (US), Bio-Rad Laboratories, Inc. (US), Merck KGaA (Germany), DiaSorin S.p.A. (Italy), Revvity, Inc. (US), and bioMérieux (France) were identified as star players, which correspondingly are supported by their strong market presence and extensive product portfolios.
-
COMPETITIVE LANDSCAPE - STARTUPS/SMEs
Randox Laboratories Ltd. (UK), Standard BioTools (US), Promega Corporation (US), Boster Biological Technology (US), and Enzo Biochem Inc. (US) have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas.
The multiplex assay market is experiencing steady growth due to the rising incidence of infectious diseases, cancer, and autoimmune conditions. This increase is expanding routine testing volumes and putting pressure on traditional single-target workflows. Additionally, precision medicine programs are gaining traction, as treatment pathways increasingly depend on biomarker stratification. Notably, the smaller sample requirements of multiplex formats make them particularly appealing in pediatrics and specialty care.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The influence of consumers on the multiplex assay market is driven by trends in healthcare demand, testing methodologies, and disruptions in diagnostic testing. Key end users of multiplex assay providers include hospitals, diagnostic centers, pharmaceutical & biotech companies, educational institutions, and contract research organizations (CROs). High-potential applications in this market include infectious diseases, cancer, autoimmune diseases, biomarkers, and companion diagnostics.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Drivers
Impact
Level
-
Rising incidence of chronic and infectious diseases
-
Increasing use of multiplex assays in companion diagnostics
RESTRAINTS
Impact
Level
-
Cost constraints associated with multiplex assay instrumentation
-
Regulatory challenges and stringent quality standards
OPPORTUNITIES
Impact
Level
-
Growing validation of biomarkers in molecular and protein-based diagnostics
-
Expansion in emerging markets
CHALLENGES
Impact
Level
-
Shortage of skilled professionals
-
Complex data analysis and interpretation
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The use of precision medicine in everyday practice has become increasingly common, driving a growing demand for multiplex tests as companion diagnostics. These multiplex tests enable the detection of multiple biomarkers from small or suboptimal biological samples. Additionally, drug developers are utilizing multiplex formats to improve patient selection and minimize inefficiencies in clinical trial screening. Importantly, a well-designed panel can significantly reduce the time between diagnosis and treatment decision.
There are still fundamental economic problems to address, such as ownership costs. Multiplex solutions will likely require upfront capital investment, which might prove problematic for smaller labs, independent diagnostic centers, and financially struggling hospitals. Apart from the upfront cost, there are service agreements, calibration procedures, middleware compatibility, reagent validation, and training costs.
Multiplex assays benefit from the emergence of a steady stream of clinically relevant markers. What researchers require now is a tool that allows the analysis of genetic, proteomic, and immune response biomarkers all together, instead of studying each one individually. This is where multiplex assays play a critical role, especially when working in oncology, autoimmune disorders, and longitudinal monitoring. Not so widely recognized is the usefulness of these assays for early assay screening and exclusion.
The adoption of technology often hinges more on the availability of skilled personnel than on the presence of equipment. In the case of multiplex assays, having knowledgeable staff is essential for proper assay setup, contamination prevention, result interpretation, and troubleshooting any equipment issues. Unfortunately, this skilled workforce is still lacking, especially in rural areas.
MULTIPLEX ASSAYS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Widely used for multiplex qPCR and immunoassay testing across infectious disease screening, oncology biomarker studies, and translational research programs where multiple analytes must be measured quickly from limited samples. | Generates demand from clinical laboratories and research centers seeking faster throughput, lower hands-on time, and consolidation of several single-target assays into one workflow. |
|
|
Uses next-generation sequencing (NGS)-based multi-panel approaches to perform genomic profiling, hereditary disorders testing, companion diagnostics, and cancer panels that demand comprehensive biomarker detection in one run. | Supports premium-value testing with higher information yield per sample. Notably, laboratories can reduce repeat testing, while pharmaceutical partnerships and oncology adoption create durable revenue channels. |
|
|
Supplies droplet digital PCR and multiplex immunoassay systems for mutation detection, gene expression analysis, residual disease monitoring, and quantitative biomarker research. | Enhances sensitivity, enables accurate quantification, and supports reproducible research outcomes. |
|
|
Focuses on multiplex molecular panels for respiratory infections, gastrointestinal pathogens, and healthcare-associated infections in acute care settings. | Creates value through faster syndromic diagnosis and reduced empiric treatment decisions | Hospitals often justify adoption through shorter isolation periods, better bed management, and improved laboratory efficiency. |
|
|
Known for multiplex syndromic tests that include sepsis, respiratory, blood stream infection, and AMR markers. | Greatest traction achieved when timely results impact patient care and treatment | Timely pathogen detection can minimize use of unnecessary antibiotics, which has become an important buying point. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The value chain for multiplex assays comprises a multilayered structure that includes consumable providers such as Merck KGaA and Thermo Fisher Scientific, platform providers such as Bio-Rad Laboratories and DiaSorin, and end users, including hospitals, clinical laboratories, pharmaceutical companies, and academic institutions. The components involved—such as beads, antibodies, primers, calibrators, and various chemistries—are integrated into platforms that measure multiple biomarkers in a single assay. Demand for these assays primarily comes from hospitals, laboratories, biopharmaceutical companies, and academic institutions, all of which require high throughput and precision. Additionally, although often overlooked, software interoperability is becoming increasingly important in purchase decisions, often competing with assay performance.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
As of 2025, consumables hold the largest share of the multiplex assay market and are expected to remain dominant through 2026. This is driven by the ongoing demand for assay kits, reagents, beads, plates, and cartridges. The frequent use of tests in diagnostics and research leads to repeat purchases, while the continuous introduction of new panels enhances long-term revenue prospects on a global scale.
As of 2025, protein multiplexing is expected to be the leading contributor to the market, with this trend projected to continue until 2026. This growth is driven by its extensive use in cytokine profiling, biomarker testing, immunohistochemistry, and cancer research applications. Bead-based and planar platforms enable the simultaneous measurement of multiple proteins from small sample sizes. The increasing demand for precision medicine and translational research continues to support steady expansion in this segment worldwide.
As of 2025, the multiplex real-time PCR segment leads the global multiplex assay market in terms of revenue and is projected to remain dominant through 2026. This leadership is due to its high sensitivity and capability for multi-parameter analyses, along with its widespread use in laboratories for immunological monitoring, cellular phenotyping, and biomarker detection.
By 2025, the research & development sector is expected to be the leading application category due to the increasing adoption of multiplex diagnostic tests for infectious diseases, cancer, autoimmune diseases, and cardiovascular diseases.
As of 2025, pharmaceutical & biotechnology companies hold the largest share of the multiplex assay market. This is due to high patient volumes, established testing infrastructure, and a growing demand for rapid diagnostics. These companies are increasingly adopting multiplex platforms to enhance turnaround times, improve workflow efficiency, and aid clinical decision-making in both routine and specialized testing.
REGION
Asia Pacific to be fastest-growing region in global multiplex assay market during forecast period
The Asia Pacific region is expected to experience the highest CAGR over the coming years, driven by improvements in healthcare facilities, a high incidence of infections requiring testing, and increased investment in advanced diagnostic techniques. Notable countries experiencing these trends include China, Japan, India, and South Korea. Other factors contributing to market growth include advancements in drug manufacturing and improved accessibility to testing solutions.
MULTIPLEX ASSAYS MARKET: COMPANY EVALUATION MATRIX
In the multiplex assay market, Thermo Fisher Scientific, Inc. (US) stands out as a dominant player, owing to its extensive assay portfolio, global distribution capabilities, and expertise in molecular diagnostics, immunoassays, and life science products. In contrast, F. Hoffmann-La Roche Ltd. (Switzerland) is positioned as an emerging leader, enhancing its market presence by developing innovative PCR-based multiplex assays. While Thermo Fisher benefits from its size, the consistent demand for consumables, and a diverse product offering, Roche demonstrates significant potential to advance into the leaders’ quadrant through an expanded product menu and solutions focused on automation.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Thermo Fisher Scientific, Inc. (US)
- Illumina, Inc (US)
- Bio-Rad Laboratories, Inc. (US)
- DiaSorin S.p.A. (Italy)
- bioMérieux (France)
- QIAGEN N.V. (Netherlands)
- Danaher Corporation (US)
- Becton, Dickinson and Company (US)
- Merck KGaA (Germany)
- Revvity, Inc. (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Agilent Technologies (US)
- Quanterix Corporation (US)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 6.65 Billion |
| Market Forecast in 2031 (Value) | USD 10.65 Billion |
| Growth Rate | CAGR of 8.3% from 2026–2031 |
| Years Considered | 2024–2031 |
| Base Year | 2025 |
| Forecast Period | 2026–2031 |
| Units Considered | Value (USD Million/Billion), Volume (Units) |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
WHAT IS IN IT FOR YOU: MULTIPLEX ASSAYS MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Country-wise analysis of multiplex assay market across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa | Detailed analysis and profiling of up to five additional market players | Expanded competitive landscape assessment with profiling and analysis of 25 key companies operating in the multiplex assay market, highlighting recent product developments, strategic investments, partnerships, and market positioning |
| Market share analysis and competitive benchmarking of key multiplex assay companies | Further breakdown of the multiplex assay market into specific countries for the Rest of Europe, the Rest of Asia Pacific, the Rest of Latin America, and the Rest of Middle East & Africa | Enhanced regional granularity through additional country-level segmentation, including Germany, the UK, France, Italy, Spain, and the Rest of Europe; China, Japan, India, and the Rest of Asia Pacific; Brazil, Mexico, and the Rest of Latin America, along with dedicated analysis for the Middle East & Africa |
| Pricing analysis of multiplex assay consumables and instruments | Country-wise regulatory and reimbursement landscape analysis for multiplex assays | Broadened market segmentation framework with the inclusion of NGS under the Technology segment, along with refined End User categorization covering Hospitals & Diagnostic Laboratories, Academic & Research Institutes, and the newly added Contract Research Organization (CROs) |
RECENT DEVELOPMENTS
- April 2026 : Thermo Fisher Scientific Inc. (US) has unveiled a VeriFlex-enabled thermal cycler that can perform multiplex assay protocols simultaneously using 3 x 32-well configurations.
- March 2026 : bioMérieux (France) announced IVDR CE marking for BIOFIRE SPOTFIRE R/ST plus Panels, enabling near-patient point-of-care multiplex PCR testing to detect common respiratory and sore throat pathogens within typical patient visit timeframes across European markets.
- February 2026 : Waters Corporation (US) successfully merged with Becton, Dickinson and Company’s (US) Biosciences and Diagnostic Solutions businesses, enhancing its multiplex assay capabilities through flow cytometry, cellular analysis, and diagnostic testing platforms.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TITLE
PAGE NO
1
INTRODUCTION
15
2
EXECUTIVE SUMMARY
3
PREMIUM INSIGHTS
4
MARKET OVERVIEW
4.1
INTRODUCTION
4.2
MARKET DYNAMICS
4.2.1
DRIVERS
4.2.2
RESTRAINTS
4.2.3
OPPORTUNITIES
4.2.5
CHALLENGES
4.3
UNMET NEEDS & WHITE SPACES
4.4
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
5.1
PORTER’S FIVE FORCES ANALYSIS
5.2
MACROECONOMIC INDICATORS
5.2.1
INTRODUCTION
5.2.2
GDP TRENDS & FORECAST
5.2.3
TRENDS IN GLOBAL MULTIPLEX ASSAY INDUSTRY
5.3
SUPPLY CHAIN ANALYSIS
5.4
VALUE CHAIN ANALYSIS
5.5
ECOSYSTEM ANALYSIS
5.6
PRICING ANALYSIS
5.6.1
AVERAGE SELLING PRICE TREND OF MULTIPLEX ASSAY PRODUCTS, BY KEY PLAYER, 2024–2026
5.6.2
AVERAGE SELLING PRICE TREND OF MULTIPLEX ASSAY PRODUCTS, BY REGION, 2024–2026
5.7
TRADE ANALYSIS
5.7.1
IMPORT SCENARIO
5.7.2
EXPORT SCENARIO
5.8
KEY CONFERENCES & EVENTS, 2026–2027
5.9
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.10
INVESTMENT & FUNDING SCENARIO
5.11
CASE STUDY ANALYSIS
5.12
IMPACT OF 2026 US TARIFFS ON MULTIPLEX ASSAY MARKET
5.12.1
INTRODUCTION
5.12.2
KEY TARIFF RATES
5.12.3
PRICE IMPACT ANALYSIS
5.12.4
IMPACT ON COUNTRIES/REGIONS
5.12.4.1
US
5.12.4.1
EUROPE
5.12.4.1
APAC
5.12.6
IMPACT ON END-USER INDUSTRIES
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1
KEY EMERGING TECHNOLOGIES
6.2
COMPLEMENTARY TECHNOLOGIES
6.3
TECHNOLOGY/PRODUCT ROADMAP
6.4
PATENT ANALYSIS
6.5
FUTURE APPLICATIONS
6.6
IMPACT OF AI/GEN AI ON MULTIPLEX ASSAY MARKET
6.6.1
TOP USE CASES & MARKET POTENTIAL
6.6.2
BEST PRACTICES IN MULTIPLEX ASSAY MARKET
6.6.3
CASE STUDIES OF AI IMPLEMENTATION IN MULTIPLEX ASSAY MARKET
6.6.4
INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS
6.6.5
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN MULTIPLEX ASSAY MARKET
7
SUSTAINABILITY & REGULATORY LANDSCAPE
7.1
REGIONAL REGULATIONS & COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2
INDUSTRY STANDARDS
7.2
SUSTAINABILITY INITIATIVES
7.2.1
ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN MULTIPLEX ASSAY MARKET
7.3
SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
7.4
CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1
DECISION-MAKING PROCESS
8.2
BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4
UNMET NEEDS FROM VARIOUS END-USER INDUSTRIES
8.5
MARKET PROFITABILITY
9
MULTIPLEX ASSAY MARKET, BY PRODUCT (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
9.1
INTRODUCTION
9.2
CONSUMABLES
9.3
INSTRUMENTS
9.4
SOFTWARE & SERVICES
10
MULTIPLEX ASSAY MARKET, BY TYPE (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
10.1
INTRODUCTION
10.2
PROTEIN MULTIPLEX ASSAYS
10.2.1
BEAD-BASED PROTEIN ASSAYS
10.2.2
PLANAR PROTEIN ASSAYS
10.2.3
OTHER PROTEIN ASSAYS
10.3
NUCLEIC ACID MULTIPLEX ASSAYS
10.3.1
BEAD-BASED NUCLEIC ACID ASSAYS
10.3.2
PLANAR NUCLEIC ACID ASSAYS
10.3.3
OTHER NUCLEIC ACID ASSAYS
10.4
CELL-BASED MULTIPLEX ASSAYS
11
MULTIPLEX ASSAY MARKET, BY TECHNOLOGY (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
11.1
INTRODUCTION
11.2
FLOW CYTOMETRY
11.3
FLUORESCENCE DETECTION
11.4
MULTIPLEX REAL-TIME PCR
11.5
LUMINESCENCE
11.6
NEXT-GENERATION SEQUENCING (NGS)
11.7
OTHER TECHNOLOGIES
12
MULTIPLEX ASSAY MARKET, BY APPLICATION (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
12.1
INTRODUCTION
12.2
RESEARCH & DEVELOPMENT
12.2.1
DRUG DISCOVERY & DEVELOPMENT
12.2.2
BIOMARKER DISCOVERY & VALIDATION
12.3
CLINICAL DIAGNOSTICS
12.3.1
INFECTIOUS DISEASES
12.3.2
CANCER
12.3.3
CARDIOVASCULAR DISEASES
12.3.4
AUTOIMMUNE DISEASES
12.3.5
NERVOUS SYSTEM DISORDERS
12.3.6
METABOLISM & ENDOCRINOLOGY DISORDERS
12.3.7
OTHER DISEASES
13
MULTIPLEX ASSAY MARKET, BY END USER (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
13.1
INTRODUCTION
13.2
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
13.3
HOSPITALS & DIAGNOSTIC LABORATORIES
13.4
ACADEMIC & RESEARCH INSTITUTES
13.5
CONTRACT RESEARCH ORGANIZATIONS
13.6
OTHER END USERS
14
CARDIAC MARKER MARKET, BY REGION (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
14.1
INTRODUCTION
14.2
NORTH AMERICA
14.2.1
US
14.2.2
CANADA
14.3
EUROPE
14.3.1
GERMANY
14.3.2
UK
14.3.3
FRANCE
14.3.4
ITALY
14.3.5
SPAIN
14.3.6
REST OF EUROPE
14.4
ASIA PACIFIC
14.4.1
JAPAN
14.4.2
CHINA
14.4.3
INDIA
14.4.4
REST OF ASIA PACIFIC
14.5
LATIN AMERICA
14.5.1
BRAZIL
14.5.2
MEXICO
14.5.3
REST OF LATIN AMERICA
14.6
MIDDLE EAST & AFRICA
15
COMPETITIVE LANDSCAPE
15.1
OVERVIEW
15.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
14.3
REVENUE ANALYSIS
15.4
MARKET SHARE ANALYSIS,
15.4.1
GLOBAL MARKET SHARE ANALYSIS
15.4.2
US MARKET SHARE ANALYSIS
15.5
BRAND COMPARISON
15.6
COMPANY EVALUATION MATRIX: KEY PLAYERS,
15.6.1
STARS
15.6.2
EMERGING LEADERS
15.6.3
PERVASIVE PLAYERS
15.6.4
PARTICIPANTS
15.6.5
COMPANY FOOTPRINT: KEY PLAYERS,
15.6.5.1
COMPANY FOOTPRINT
15.6.5.2
REGION FOOTPRINT
14.6.5.3
PRODUCT & SERVICE FOOTPRINT
15.6.5.4
APPLICATION FOOTPRINT
15.6.5.5
END-USER FOOTPRINT
15.7
COMPANY EVALUATION MATRIX: STARTUPS/SMES,
15.7.1
PROGRESSIVE COMPANIES
15.7.2
RESPONSIVE COMPANIES
15.7.3
DYNAMIC COMPANIES
15.7.4
STARTING BLOCKS
15.7.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES,
15.7.5.1
DETAILED LIST OF KEY STARTUPS/SMES
15.7.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
15.8
COMPANY VALUATION & FINANCIAL METRICS
15.9
COMPETITIVE SCENARIO
15.9.1
PRODUCT LAUNCHES
15.9.2
DEALS
15.9.3
EXPANSIONS
16
COMPANY PROFILES
16.1
KEY PLAYERS
16.1.1
THERMO FISHER SCIENTIFIC, INC. (US)
16.1.2
ILLUMINA, INC (US)
16.1.3
BIO-RAD LABORATORIES, INC. (US)
16.1.4
QIAGEN N.V. (NETHERLANDS)
16.1.5
DANAHER CORPORATION (US)
16.1.6
BECTON DICKINSON AND COMPANY (US)
16.1.7
MERCK KGAA (GERMANY)
16.1.8
DIASORIN S.P.A. (ITALY)
16.1.9
REVVITY, INC. (US)
16.1.10
F. HOFFMANN-LA ROCHE LTD. (SWITZERLAND)
16.1.11
AGILENT TECHNOLOGIES (US)
16.1.12
QUANTERIX CORPORATION (US)
16.1.13
BIOMÉRIEUX (FRANCE)
16.2
OTHER PLAYERS
16.2.1
BIO-TECHNE CORPORATION (US)
16.2.2
SEEGENE INC.(SOUTH KOREA)
16.2.3
MESO SCALE DIAGNOSTICS, LLC (US)
16.2.4
RANDOX LABORATORIES LTD. (UK)
16.2.5
STANDARD BIOTOOLS (US)
16.2.6
HOLOGIC, INC. (US)
16.2.7
ABBOTT LABORATORIES (US)
16.2.8
SIEMENS HEALTHINEERS (GERMANY)
16.2.9
ENZO BIOCHEM INC. (US)
16.2.10
SHIMADZU CORPORATION (JAPAN)
16.2.11
PROMEGA CORPORATION (US)
16.2.12
BOSTER BIOLOGICAL TECHNOLOGY (US)
17
RESEARCH METHODOLOGY
17.1
RESEARCH DATA
17.1.1
SECONDARY DATA
17.1.1.1
KEY DATA FROM SECONDARY SOURCES
17.1.2
PRIMARY DATA
17.1.2.1
KEY DATA FROM PRIMARY SOURCES
17.1.2.2
KEY PRIMARY PARTICIPANTS
17.1.2.3
BREAKDOWN OF PRIMARY INTERVIEWS
17.1.2.4
KEY INDUSTRY INSIGHTS
17.2
MARKET SIZE ESTIMATION
17.2.1
BOTTOM-UP APPROACH
17.2.2
TOP-DOWN APPROACH
17.2.3
BASE NUMBER CALCULATION
17.3
MARKET FORECAST APPROACH
17.3.1
SUPPLY SIDE
17.3.2
DEMAND SIDE
17.4
DATA TRIANGULATION
17.5
FACTOR ANALYSIS
17.6
RESEARCH ASSUMPTIONS
17.7
RESEARCH LIMITATIONS & RISK ASSESSMENT
18
APPENDIX
18.1
DISCUSSION GUIDE
18.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.3
CUSTOMIZATION OPTIONS
18.4
RELATED REPORTS
18.5
AUTHOR DETAILS
Methodology
The objective of this study is to analyze key market dynamics, including drivers, opportunities, restraints, and challenges, as well as the strategies of major players. It aims to monitor developments across leading players, including acquisitions, product launches, expansions, agreements, and partnerships. Additionally, the study will examine the competitive landscape of the multiplex assay market by evaluating market participants based on various criteria within the overarching categories of business and product strategy. To estimate the market size, both top-down and bottom-up approaches were employed. The market breakdown and data triangulation methods were used to assess segment and subsegment sizes.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were primarily industry experts from core and related industries, as well as preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations across all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.
Note 1: C-level primaries include CEOs, CFOs, COOs, and VPs.
Note 2: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
Note 3: Companies are classified into tiers based on their total revenue. The tiers are as follows: Tier 1 = >USD 10 billion, Tier 2 = USD 1 billion to USD 10 billion, and Tier 3 = <USD 1 billion.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
For the global market value, annual revenue figures were calculated using revenue mapping for major product manufacturers and OEMs active in the global multiplex assay market. All major product manufacturers were identified at the global and/or country/regional level. Revenue mapping for the respective business segments/subsegments was done for the major players. Also, the global multiplex assay market was split into various segments and sub-segments:
- List of major players operating in the products market at the regional and/or country level
- Product mapping of various multiplex assay manufacturers at the regional and/or country level
- Mapping of annual revenue generated by listed major players from multiplex assay (or the nearest reported business unit/product category)
- Extrapolation of the revenue mapping of the listed major players to derive the global market value of the respective segments/subsegments
- Summation of the market value of all segments/subsegments to arrive at the global multiplex assay market
The data mentioned above was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.
Market Size Estimation (Bottom-up & Top-down Approaches)
Data Triangulation
After determining the overall size of the global multiplex assay market using the methodology described above, the market was segmented into several segments and subsegments. The data triangulation and market breakdown procedures were employed, as applicable, to complete the overall market engineering process and obtain exact market value data for the key segments and subsegments. The extrapolated market data was triangulated by studying various macroindicators and regional trends from both demand- and supply-side participants.
Market Definition
The multiplex assay market comprises analytical testing platforms that enable the qualitative and quantitative assessment of multiple analytes from a single biological sample in a single run. These platforms offer advantages such as reduced testing time, increased automation, and the need for fewer biological samples compared to singleplex assays. The industry encompasses instrumentation, reagents, software, and other services utilized for a wide range of applications globally.
Key Stakeholders
- Manufacturers of multiplex assay products
- Suppliers and distributors of multiplex assay products
- Hospitals
- Diagnostic, clinical, and research laboratories
- Research & development (R&D) companies
- Group purchasing organizations (GPOs)
- Medical research laboratories
- Academic medical centers and universities
- Corporate entities
- Accountable care organizations (ACOs)
- Community centers
- Government institutes
- Market research and consulting firms
- Contract manufacturing organizations (CMOs)
- Contract research organizations (CROs)
- Venture capitalists and investors
Report Objectives
- To define, describe, segment, and forecast the multiplex assay market by product & service, type, technology, application, end user, and region
- To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall multiplex assay market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the multiplex assay market in five main regions (along with their respective key countries): North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players in the multiplex assay market and comprehensively analyze their core competencies and market shares
- To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, partnerships, and R&D activities of the leading players in the multiplex assay market
- To benchmark players within the multiplex assay market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
Available customizations:
Based on the given market data, MarketsandMarkets offers customizations tailored to your company’s specific needs. The following customization options are available for the report:
GEOGRAPHIC ANALYSIS
- Further breakdown of the Rest of Europe multiplex assay market into Russia, Switzerland, Denmark, Austria, and others
- Further breakdown of the Rest of Asia Pacific multiplex assay market into South Korea, Taiwan, and others
- Further breakdown of the Rest of Latin America multiplex assay market into Argentina, Colombia, Chile, Ecuador, and others
- Further breakdown of the Southeast Asia multiplex assay market into Malaysia, Singapore, Australia, New Zealand, and others
COMPETITIVE LANDSCAPE ASSESSMENT
- Market Share Analysis, by region (North America and Europe), which provides the market share of the top 3 to 5 key players in the multiplex assay market
- Competitive leadership mapping for established players in the US
⚡ Growth Signals
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Multiplex Assays Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
JAYANT RAJPUROHIT
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Company
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
BEATRIZ DE LA CALLE
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Company
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Bob Williams,
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnostics
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Cody Coonradt,
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
Still Researching the
Multiplex Assays Ecosystem?
See the competitors, opportunities, and growth signals shaping it - instantly.
Generate 15+ consulting-grade strategic insights tailored to your growth question.
Explore Multiplex Assays Intelligence
Powered by 17 years of MarketsandMarkets intelligence
